Posts

AstraZeneca wins FDA nod for first‑in‑class blood pressure pill Baxfendy

on

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

on

AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial

on

AstraZeneca gears up for FDA filing after baxdrostat's phase 3 hypertension success

on

AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition

on